Live Breaking News & Updates on Miconazole Domiphen Bromide

Stay updated with breaking news from Miconazole domiphen bromide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms with the combination of Miconazole (2%) and Domiphen Bromide (0.14% or 0.29%) demonstrated excellent safety and tolerability Low dose (0.14%) showed significant improvement over active control in clinical and mycological outcome at day 291 Liège, Belgium – 30 January 2024, 07:00 AM CET – Regulated information – Inside information – Hyloris Pha ....

Miconazole Domiphen , Jean Luc Vandebroek , Stijn Van Rompay , Hyloris Pharmaceuticals , Purna Pharmaceuticals , Hyloris Pharmaceuticals Sa Euronext Brussels , Purna Female Healthcare Announce Positive Results , Acute Vulvovaginal Candidiasis , Domiphen Bromide , Euronext Brussels , Miconazole Domiphen Bromide , Van Rompay , Chief Executive Officer , Female Healthcare , Luc Vandebroek , Lancet Infectious Diseases , Clinical Infectious Diseases , Expert Opinion , Vulvovaginal Candidiasis , Domiphen Bromide , Clinical Outcome , The Company , Euronext Brussels , Stijn Van Rompay ,

Hyloris and Purna Female Healthcare Announce Positive

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC) Both treatment arms. ....

Jean Luc Vandebroek , Miconazole Domiphen , Stijn Van Rompay , Hyloris Pharmaceuticals Sa Euronext Brussels , Purna Pharmaceuticals , Hyloris Pharmaceuticals , Purna Female Healthcare Announce Positive Results , Acute Vulvovaginal Candidiasis , Domiphen Bromide , Euronext Brussels , Miconazole Domiphen Bromide , Van Rompay , Chief Executive Officer , Female Healthcare , Luc Vandebroek , Lancet Infectious Diseases , Clinical Infectious Diseases , Expert Opinion , Brussels Stock Exchange Hyl , Hyloris Pharmaceuticals Sa , Phase 2 , Positive Results , Emale Healtcare , Purna Female Healthcare ,

Hyloris And Purna Female Healthcare Announce Positive Results From Phase 2 Trial In Patients With Acute Vulvovaginal Candidiasis (VVC)

Hyloris And Purna Female Healthcare Announce Positive Results From Phase 2 Trial In Patients With Acute Vulvovaginal Candidiasis (VVC)
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Jean Luc Vandebroek , Miconazole Domiphen , Stijn Van Rompay , Purna Pharmaceuticals , Global Info Research , Hyloris Pharmaceuticals , Hyloris Pharmaceuticals Sa Euronext Brussels , Purna Female Healthcare Announce Positive Results , Acute Vulvovaginal Candidiasis , Domiphen Bromide , Euronext Brussels , Miconazole Domiphen Bromide , Van Rompay , Chief Executive Officer , Female Healthcare , Luc Vandebroek , Lancet Infectious Diseases , Clinical Infectious Diseases , Expert Opinion ,

Hyloris Announces Start of Phase 2 Study of Miconazole-Domiphen Bromide Vaginal Cream in ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

Stijn Van Rompay , Purna Female Health , Hyloris Pharmaceuticals Sa Euronext Brussels , Hyloris Pharmaceuticals , Global Info Research , Miconazole Domiphen Bromide , Euronext Brussels , Purna Female , Van Rompay , Chief Executive Officer , Domiphen Bromide , Candida Infections , Investor Relations , Lancet Infectious Diseases , Clinical Infectious Diseases , Expert Opinion , Globe Newswire , Yeast Infections , Hyloris Pharmaceuticals Sa ,

Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead
Hyloris Pharmaceuticals SAAugust 4, 2021 GMT
On target to grow the broad product pipeline with at least 3 additional programmes before end 2021
Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV
Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end
€53.47 million in cash and cash equivalents to execute ambitious growth strategy
Conference call and webcast today at 3pm CEST/9am EST (details below)
Liège, Belgium – 4 August 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today reports its condensed consolidated financial results for the six-month p ....

United States , United Kingdom , Marieke Vermeersch , Stijn Van Rompay , Miconazole Domiphen , Olivier Declercq , Chris Buyse , Alter Pharma Group For Maxigesic , Alter Pharma Group , International Standard On Review Engagements , Hyloris Pharmaceuticals , Company Group Structure , Hyloris Pharmaceuticals Sa Euronext Brussels , Corporate Communications , Pharma Bavaria International , Hikma Pharmaceuticals , Euronext Brussels , Van Rompay , Chief Executive Officer , South America , Latin America , Purna Female Healthcare , Miconazole Domiphen Bromide , Tranexamic Acid , Fusidic Acid , Alter Pharma ,